Mr. Ken d'Entremont reports

MEDEXUS HOLDS ANNUAL MEETING OF SHAREHOLDERS AND ANNOUNCES ELECTION OF DIRECTORS

Medexus Pharmaceuticals Inc. today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated Aug. 10, 2026, as directors through the next annual meeting. Shareholders also voted in favour of the appointment of PricewaterhouseCoopers LLP as the company's auditor and in favour of resolutions amending the company's equity incentive compensation plan.

Detailed voting results for the election of directors are set out in the attached table.

Shareholders also cast 13,812,075 (99.560 per cent) votes for and withheld 61,000 (0.440 per cent) votes from the appointment of PricewaterhouseCoopers as the company's auditor, and cast 10,906,889 (94.912 per cent) votes for and 584,632 (5.088 per cent) votes against the resolutions amending Medexus's equity incentive compensation plan. All proposals were therefore approved.

A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities on SEDAR+.

About Medexus Pharmaceuticals Inc.

Medexus is a leading pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on hematology and hemato-oncology products, including cell and gene therapy products, and historically also on rheumatology and allergy products.

We seek Safe Harbor.